Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of StreptAnova Vaccine in Healthy Adults
NCT02564237Phase 1Unknown
- Sponsor
- Dalhousie University
- Start
- Aug 2015
- Primary completion
- Mar 2017
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of StreptAnova in Group A streptococcal infection (2 arms), sponsored by Dalhousie University. Primary endpoint: Occurrence of adverse events. Status: unknown.
02
Drugs
StreptAnova
03
Conditions
Group A streptococcal infection
Beyond the preview
Go deeper on NCT02564237.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02564237.